Pancreatic Cancer: Basic Mechanisms and Therapies

1. Notch signaling pathway in pancreatic tumorigenesis
Keli Xu
2. EMT in Pancreatic Ductal Adenocarcinoma
Azeddine Atfi
3. Review of Immunocompetent In-vivo Models of PDAC OR Stromal Microenvironment Impact on Pacreatic Cancer Progression and Metastasis
Vignesh Vudatha and Jose Trevino
4. Interplay between MAP Kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer
Ajay Rana and Kumar Sandeep
5. KRAS in pancreatic cancer: Emerging therapeutic strategies
Daohong Zhou
6. Disparities in Pancreatic Cancer Clinical Trials
Allison Neal Martin and Rebecca A. Snyder
7. Tumor heterogeneity: an oncogenic driver of PDAC progression and therapy resistance under stress conditions
Esha Madan
8. Oncogenic Signaling Pathways in Pancreatic Ductal Adenocarcinoma
Kedar Nath Natarajan
9. Chemoresistance in Pancreatic Ductal Adenocarcinoma: Overcoming Resistance to Therapy
Praveen Bhoopathi
10. Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma
Rajan Gogna

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Biologia Celular (citologia)
• Genética (não médica)
• Imunologia
• Oncologia
• Microbiologia (não médica)

Acinar-to-ductal metaplasia (ADM); Autophagy; Cancer cell-of-origin; Cancer disparities; cancer stem cell; Cancer stem cell; Cancer stem cells; Chemoresistance; Chemosensitization; Clinical trials; Combinatorial therapy; CRISPR; Drug resistance; EMT; EMT-transcription factor; Epithelial to mesenchymal transition; Epithelial-mesenchymal transition (EMT); Epithelial-to-mesenchymal transition; Extra cellular vesicles; Extracellular matrix; Gemcitabine; Genetically engineered mouse models; Immune checkpoint proteins; Immunotherapy; In vivo models; Intraductal papillary mucinous neoplasm (IPMN); KRAS; lncRNA; MAPK signaling cascade; Metabolism; Metastasis; Microbiome; Microenvironment; miRNA; Mitogen-activated protein kinase; MYC; Notch signaling pathway; Oncogenic signaling; Pancreas cancer; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreatic ductal adenocarcinoma (PDAC); Pancreatic intraepithelial neoplasia (PanIN); Pancreatic neuroendocrine tumor (PNET); PanIN; Patient derived xenograft; PDAC; Resistance; Senescence; Single-cell transcriptomics; Stress conditions; Targeted therapy; TGF-? pathway; Therapeutics targeting PDAC; Therapy; Tumor heterogeneity; Tumor microenvironment